EDIT: Editas Medicine Inc Market Cap to Revenue Ratio

Symbol and logo of brand Editas (EDIT)

The price-to-sales chart for Editas Medicine, Inc. (EDIT), which attracts leading geneticists to advance CRISPR technologies, illustrates current dynamics where the 5.80 mark serves as a key metric. The company's foundation is built on genome editing patents, while future revenues will be based on therapies for ophthalmological and hematological pathologies following the completion of clinical trials.

Editas Medicine (EDIT): P/S Multiple from 07/04/2022 to 11/17/2026

Metric breakdowns and analytics for Editas Medicine (EDIT)

- current quotes and average value forecast:
General company analysis:EDIT - Editas
Core merchandise of editasmedicine.com

Analyzing the market value of Editas Medicine, Inc. (EDIT) relative to its annual sales helps identify whether the asset is overbought or potentially undervalued, thereby mitigating the risk of capital freeze. Amidst a stable R&D backdrop for US biotechs, this revenue-based valuation of Editas Medicine, Inc. (EDIT) compares current market capitalization with actual earnings, demonstrating resource management efficiency during the period of post-crisis business recovery.

Who Editas Medicine, Inc. competes with

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|NTLA (Intellia Therapeutics, Inc.) - Price-to-Sales Ratio|Stoke Corp - P/S Multiple|BLFS (BioLife) - Market Cap to Revenue Ratio|wavelifesciences.com (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics, Inc.) - P/S Multiple|Market Cap to Revenue Prime Medicine Corp (PRME)|P/S Multiple TSHA|P/S Multiple uniQure N.V. (QURE)|Price-to-Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc - P/S Multiple|OCGN - P/S Multiple|PACB: P/S Multiple|BNTC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Design Therapeutics, Inc.|RCKT: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Korro Bio, Inc. KRRO|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio